Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group.

J Hepatol. 2003 Jan;38(1):51-8.

PMID:
12480560
2.
3.

Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.

Pedretti G, Calzetti C, Missale G, Fiaccadori F.

Ital J Gastroenterol. 1991 May;23(4):175-8.

PMID:
1751811
4.

Rifaximin treatment in hepatic encephalopathy.

Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP.

N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.

5.

Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). A controlled trial.

Heredia D, Caballería J, Arroyo V, Ravelli G, Rodés J.

J Hepatol. 1987 Jun;4(3):293-8.

PMID:
3598162
6.

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.

Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK.

Am J Gastroenterol. 2013 Sep;108(9):1458-63. doi: 10.1038/ajg.2013.219. Epub 2013 Jul 23.

PMID:
23877348
7.

RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.

Schulz C, Schütte K, Kropf S, Schmitt FC, Vasapolli R, Kliegis LM, Riegger A, Malfertheiner P.

Trials. 2016 Feb 29;17(1):111. doi: 10.1186/s13063-016-1205-8.

8.
9.

Rifaximin for the treatment of hepatic encephalopathy.

Lawrence KR, Klee JA.

Pharmacotherapy. 2008 Aug;28(8):1019-32. doi: 10.1592/phco.28.8.1019. Review.

PMID:
18657018
10.
11.

Rifaximin for treatment of hepatic encephalopathy.

Maclayton DO, Eaton-Maxwell A.

Ann Pharmacother. 2009 Jan;43(1):77-84. doi: 10.1345/aph.1K436. Epub 2008 Dec 17. Review.

PMID:
19092143
12.

Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial.

Uribe M, Campollo O, Vargas F, Ravelli GP, Mundo F, Zapata L, Gil S, Garcia-Ramos G.

Hepatology. 1987 Jul-Aug;7(4):639-43.

PMID:
3301614
13.

Treatment of porto-systemic encephalopathy with lactitol verus lactulose: a randomized controlled study.

Pai CH, Huang YS, Jeng WC, Chan CY, Lee SD.

Zhonghua Yi Xue Za Zhi (Taipei). 1995 Jan;55(1):31-6.

PMID:
7712392
14.

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.

Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP.

Aliment Pharmacol Ther. 2011 Oct;34(8):853-61. doi: 10.1111/j.1365-2036.2011.04808.x. Epub 2011 Aug 17.

15.

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis.

Bajaj JS, Barrett AC, Bortey E, Paterson C, Forbes WP.

Aliment Pharmacol Ther. 2015 Jan;41(1):39-45. doi: 10.1111/apt.12993. Epub 2014 Oct 22.

16.

Rifaximin: new therapeutic indication and future directions.

Rivkin A, Gim S.

Clin Ther. 2011 Jul;33(7):812-27. doi: 10.1016/j.clinthera.2011.06.007. Epub 2011 Jul 7. Review.

PMID:
21741091
17.

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

Miglio F, Valpiani D, Rossellini SR, Ferrieri A.

Curr Med Res Opin. 1997;13(10):593-601.

PMID:
9327194
18.

Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial.

Uribe M, Toledo H, Perez F, Vargas F, Gil S, Garcia-Ramos G, Ravelli GP, Guevara L.

Dig Dis Sci. 1987 Dec;32(12):1345-53.

PMID:
3319453
19.

Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy.

Heredia D, Terés J, Orteu N, Rodés J.

J Hepatol. 1988 Aug;7(1):106-10.

PMID:
3053887
20.

Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy.

Salerno F, Moser P, Maggi A, Vitaliani G, Benetti G.

J Hepatol. 1994 Dec;21(6):1092-6.

PMID:
7699233

Supplemental Content

Support Center